WO2004000206A2 - Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same - Google Patents

Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2004000206A2
WO2004000206A2 PCT/KR2003/001172 KR0301172W WO2004000206A2 WO 2004000206 A2 WO2004000206 A2 WO 2004000206A2 KR 0301172 W KR0301172 W KR 0301172W WO 2004000206 A2 WO2004000206 A2 WO 2004000206A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
derivative
pyrazole
acid
pharmaceutical composition
Prior art date
Application number
PCT/KR2003/001172
Other languages
French (fr)
Other versions
WO2004000206A3 (en
Inventor
Il-Hwan Cho
Ji-Young Noh
Sang-Wook Park
Hyung-Chul Ryu
Jee-Woong Lim
Jong-Hoon Kim
Myeong-Yun Chae
Dal-Hyun Kim
Sung-Hak Jung
Hyun-Jung Park
Young-Hoon Kim
In-Ki Min
Original Assignee
Cj Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Corporation filed Critical Cj Corporation
Priority to JP2004515206A priority Critical patent/JP4257292B2/en
Priority to EP03760957A priority patent/EP1515952A4/en
Priority to AU2003232684A priority patent/AU2003232684A1/en
Publication of WO2004000206A2 publication Critical patent/WO2004000206A2/en
Publication of WO2004000206A3 publication Critical patent/WO2004000206A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Definitions

  • the present invention relates to a pyrazole-3-one derivative or a non-toxic salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient.
  • Nonsteroidal antiinflammatory agents are responsible for blocking enzyme, cyclooxygenase (COX) or prostaglandin G/H synthase, to reduce inflammation, pain, or fever. In addition, they inhibit uterus contraction caused by hormones and also inhibit growth of several cancers.
  • Cyclooxygenase-1 (COX-1 ) was first discovered in bovine. The COX-1 is constitutively expressed in a variety of cell types. Unlike the COX-1 , cyclooxygenase-2 (COX-2) is a recently discovered isoform of cyclooxygenase that can be easily induced by mitogen, endotoxin, hormone, growth factor, or cytokine. Prostaglandin is a potent mediator for various pathological and physiological processes.
  • the COX-1 plays important physiological roles such as in the release of endogenous prostaglandin, the maintenance of the shape and the function of stomach, and the blood circulation in the kidney.
  • the COX-2 is induced by an inflammatory factor, hormone, a growth factor, or cytokine. Therefore, the COX-2 is involved in pathological processes of prostaglandin, unlike the constitutive COX-1.
  • selective inhibitors of the COX-2 produce fewer and less side effects in terms of action mechanism in comparison with conventional nonsteroidal antiinflammatory agents.
  • they reduce inflammation, pain, and fever and inhibit uterus contraction caused by hormones and growth of several cancers.
  • they are effective in decreasing side effects such as stomach toxicity and kidney toxicity.
  • they inhibit the synthesis of contractile prostanoid, thereby leading to suppression of the contraction of smooth muscles. Therefore, they help in preventing premature birth, menstrual irregularity, asthma, and eosinophilic disease.
  • a selective COX-2 inhibitor having a diaryl heterocyclic structure i.e. a tricyclic structure has been widely studied as a potent candidate.
  • the diaryl heterocyclic structure has a central ring and a sulfonamide or methylsulfone group attached to one of the aryl rings.
  • An initial substance having such diaryl heterocyclic structure is Dup697 [Bioorganic & Medicinal Chemistry Letters, Vol 5, p2123, 1995].
  • Celecoxib of formula 14 is disclosed in U.S. Patent No. 5,466,823.
  • the Celecoxib is a substituted pyrazolyl benzenesulfonamide derivative.
  • Rofecoxib of formula 15 Another selective COX-2 inhibitor, Rofecoxib of formula 15 is disclosed in WO 95/00501.
  • the Rofecoxib has a diaryl heterocyclic structure with a central furanone ring.
  • Valdecoxib of formula 16 as another selective COX-2 inhibitor is disclosed in U.S. Patent No. 5,633,272.
  • the Valdecoxib has a phenylsulfonamide moiety with a central isoxazole ring.
  • the selective COX-2 inhibitors of formulas 14 to 16 are effective inflammatory therapeutic agents with fewer and less side effects in comparison with conventional nonsteroidal antiinflammatory agents.
  • An aspect of the present invention provides a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof.
  • Another aspect of the present invention provides a method for preparing a pyrazole-3-one derivative or a non-toxic salt thereof.
  • Another aspect of the present invention provides a pharmaceutical composition comprising a pyrazole-3-one derivative or a non-toxic salt thereof as an active ingredient for the treatment of fever, pain, and inflammation.
  • Yet another aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pyrazole-3-one derivative or a non-toxic salt thereof as an active ingredient for the treatment of cancers and dementia.
  • R ⁇ and R 2 each independently represent C ⁇ -C 3 alkyl, aryl, or substituted aryl;
  • R 3 represents amino or methyl
  • R4 and R 5 each independently represent hydrogen, C ⁇ -C 3 alkyl, halogen, methyl substituted with halogen, C C 3 alkoxy, cyano, or nitro; or a non-toxic salt thereof.
  • the Ri and R 2 each independently represent C ⁇ -C 3 alkyl; R 3 represents methyl; and R 4 and Rs each independently represent hydrogen, C ⁇ -C 3 alkyl, halogen, or C ⁇ -C 3 alkoxy.
  • R 4 and R 5 are respectively 3- and 4-, 2- and 4-, 3- and 5-, or 3- and 2-, and more preferably 3- and 4-.
  • the pyrazole-3-one derivative of formula 1 may be present in a form of a non-toxic salt.
  • non-toxic salt refers to a pharmaceutically acceptable, toxin-free salt, including an organic salt and an inorganic salt.
  • the Inorganic salt of the pyrazole-3-one derivative of formula 1 includes an inorganic salt of aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, or zinc but is not limited thereto.
  • an inorganic salt of ammonium, calcium, potassium, or sodium is used.
  • the organic salt of the pyrazole-3-one derivative of formula 1 includes an organic amine salt of primary, secondary, or tertiary amine, substituted amine that is present in nature, or cyclic amine, or a salt of a basic ion exchange resin but is not limited thereto.
  • the salt of a basic ion exchange resin include a salt of arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine,
  • the pyrazole-3-one derivative of formula 1 may be present in a form of an organic acid salt or an inorganic acid salt.
  • the organic acid salt or the inorganic acid salt of the pyrazole-3-one derivative of formula 1 include a salt of acetic acid, adipic acid, aspartic acid, 1 ,5-naphthalene disulfonic acid, benzene sulfonic acid, benzoic acid, camphor sulfonic acid, citric acid, 1 ,2-ethane disulfonic acid, ethane sulfonic acid, ethylenediaminetetraacetic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, icethionic acid, lactic acid, maleic acid, malic acid, madelic acid, methane sulfonic acid, mucinic acid, 2-naphthalenedisulfonic acid, nitric
  • the pyrazoIe-3-one derivative of the present invention preferably includes: 5-(4-methanesulfonylphenyl)-4-(4-methoxyphenyl)-1 ,2-dimethyl-1 ,2-dihyd ropyrazole-3-one;
  • R 3 , R 4 , and R 5 are as defined in formula 1 and RQ represents CrC 3 alkyl.
  • a method for preparing a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof comprising reacting a hydrazine derivative of formula 5 with a propionic acid derivative of formula 4.
  • Ri and R 2 are as defined in formula 1 .
  • the aforementioned reactions are preferably carried out in a solvent which can be separated from water produced during the reaction by a Dean-Stark trap apparatus.
  • the solvent include, but are not limited to, benzene, toluene, or xylene. More preferably, toluene is used.
  • the reactions are preferably carried out by heating the reactant to the boiling point of the solvent and completing the reaction. More preferably, toluene is used as a solvent and the reactants are heated to the boiling point of the tolene and refluxed to complete the reaction.
  • the separation and purification of the reaction products can be performed by concentration or extraction, or other processes, which is conventionally used in organic synthesis process, and optionally by a silica gel column chromatography.
  • the said propionic acid derivative of formula 4 may be prepared by reacting a sulfonylbenzoic acid derivative of formula 2 with a phenyl acetate derivative of formula 3 in the presence of a base.
  • R 3 , R 4 , and R 5 are as defined in formula 1 and RQ represents C ⁇ -C 3 alkyl.
  • the said base includes sodium hydride, potassium carbonate, or potassium hydroxide.
  • sodium hydride is used.
  • a pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier for the treatment of fever, pain, and inflammation.
  • the pharmaceutical composition comprises a compound of formula 1 or a non-toxic salt thereof when it is a selective inhibitor of cyclooxygenase-2. Therefore, the pharmaceutical composition can be used as an antipyretic, an analgesic, and an antiinflammatory agent, with reduced side effects.
  • a compound of formula 1 and a non-toxic salt thereof selectively inhibit cyclooxygenase-2. Therefore, the side effects of conventional nonsteroidal antipyretics, analgesics, and antiinflammatory agents can be reduced.
  • the pharmaceutical composition of the present invention comprises a compound of formula 1 and/or a non-toxic salt thereof and a pharmaceutically acceptable carrier or excipient. Therefore, the pharmaceutical composition may be used as a substitute for conventional nonsteroidal antiinflammatory agents.
  • the pharmaceutical composition of the present invention is useful for treating patients with peptic ulcer, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.
  • the pharmaceutical composition of the present invention can be used in all inflammatory diseases associated with pathological prostaglandin and is particularly useful in treating osteoarthritis and rheumatoid arthritis which require high dosage of nonsteroidal antiinflammatory agents .
  • the pharmaceutical composition of the present invention can be administered in form of an adult dosage of 50 mg/kg/day to 400 mg/kg/day of the compound of formula 1. An adequate dosage is determined depending on the degree of disease severity.
  • a pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof and a pharmaceutically acceptable carrier for the treatment of cancers and dementia.
  • nonsteroidal antiinflammatory agents are effective in the treatment of large intestine cancer [European Journal of Cancer, Vol 37, p2302, 2001], prostate cancer [Urology, Vol 58, p127, 2001], and dementia [Exp. Opin. Invest. Drugs, Vol 9, p671 , 2000]. Therefore, it is understood that the pharmaceutical composition of the present invention as a nonsteroidal antiinflammatory agent can also be used for the treatment of these diseases.
  • the pharmaceutical composition of the present invention can be administered in the form of an adult dosage of 50 mg/kg/day to 400 mg/kg/day of the compound of formula 1 or a non-toxic salt thereof.
  • An adequate dosage is determined depending on the degree of disease severity.
  • the pharmaceutical composition of the present invention may be administered in the form of tablet, foam tablet, capsule, granule, powder, sustained-release tablet, sustained-release capsule (a single unit formulation or a multiple unit formulation), intravenous and intramuscular injectable solution, infusion solution, suspension, or suppository, or in other suitable dosage forms.
  • Sustained-release pharmaceutical dosage forms contain active ingredients with or without an initial loading dose. They are wholly or partially sustained-release pharmaceutical dosage forms to release active ingredients in a controlled manner.
  • the pharmaceutical composition is orally administered.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient and/or diluent and/or adjuvant in pharmaceutically effective amounts.
  • excipient and adjuvant examples include gellatin, a natural sugar such as sucrose and lactose, lecitin, pectin, starch such as corn starch and amylose, cyclodextrin and cyclodextrin derivative, dextran, polyvinylpyrrolidone, poiyvinyl acetate, Arabic gum, arginic acid, xylose, talc, salicylic acid, calcium hydrogen phosphate, cellulose, cellulose derivative such as methylcellulose, methoxypropyl cellulose, hydroxypropylmethyl cellulose, and hydroxypropylmethylcellulose phthalate, fatty acid having 12 to 22 carbon atoms, emulsifying agent, oil and fat, in particular, vegetable glycerol ester and polyglycerol ester of saturated fatty acids, monohydric alcohol, polyhydric alcohol, polyglycol such as polyethylene glycol, aliphatic alcohol having 1 to 20 carbon atoms, or aliphatic saturated or unsaturated
  • the disintegrating agent examples include a cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, sodium carboxymethyl cellulose, and microcrystalline cellulose.
  • a coating agent which is conventionally used in this field may also be used.
  • the coating agent include acrylic acid and/or methacrylic acid and/or an ester polymer or copolymer thereof, zein, ethyl cellulose, ethyl cellulose succinate, and Shellac.
  • a plasticizer suitable for the coating agent is citric ester and tartaric ester, glycerol and glycerol ester, or polyethylene glycol with different chain lengths.
  • a liquid composition such as solution and suspension is formulated in water or a physiological acceptable organic solvent such as alcohol and aliphatic alcohol.
  • the liquid pharmaceutical composition may further comprise a preservative such as potassium solvate, methyl 4-hydroxybenzoate, and propyl 4-hydroxybenzoate, an antioxidant such as ascorbic acid, and a fragrant such as peppermint oil.
  • a preservative such as potassium solvate, methyl 4-hydroxybenzoate, and propyl 4-hydroxybenzoate
  • an antioxidant such as ascorbic acid
  • a fragrant such as peppermint oil.
  • liquid pharmaceutical composition when the liquid pharmaceutical composition is formulated, a conventional solubilizer or emulsifier such as polyvinylpyrrolidone and polysolvate 80 may be used.
  • U-937 human lymphoma cells (Korean Cell Line Bank, Seoul, Korea, Accession Number: 21593) were cultured and centrifuged. The collected cells were diluted with HBSS (x1 , Hank's balanced salt solution) to a concentration of 1 x 10 6 cells/ml. 1 ml of the dilute cell solution was placed into each well of 12-well plates. 5 ⁇ JL of 1 ⁇ M solution of a test compound in DMSO and 5 ⁇ i of DMSO as a control were added to the wells. The wells were incubated in C0 2 incubator at 37 " C for 15 minutes.
  • HBSS Hank's balanced salt solution
  • % Inhibition (concentration of PGE2 in test compound-untreated sample - concentration of PGE2 in test compound-treated sample) / (concentration of PGE2 in test compound-untreated sample) x 100
  • the compounds of Examples 5 to 7 exhibited the COX-2 inhibitory activities significantly higher than the reference. Based on this result, it can be seen that the present compounds have reduced side effects due to enhanced selectivity and improved relief effects of fever, pain, and inflammation, compared to the reference.
  • the present invention provides a pyrazole-3-one derivative or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient.
  • the pharmaceutical composition is effective in reducing fever, pain, and inflammation.
  • the pharmaceutical composition is useful for treating patients with peptic ulcer disease, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Description

PYRAZOLE-3-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE
SAME
Technical Field
The present invention relates to a pyrazole-3-one derivative or a non-toxic salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient.
Background Art
Most nonsteroidal antiinflammatory agents are responsible for blocking enzyme, cyclooxygenase (COX) or prostaglandin G/H synthase, to reduce inflammation, pain, or fever. In addition, they inhibit uterus contraction caused by hormones and also inhibit growth of several cancers. Cyclooxygenase-1 (COX-1 ) was first discovered in bovine. The COX-1 is constitutively expressed in a variety of cell types. Unlike the COX-1 , cyclooxygenase-2 (COX-2) is a recently discovered isoform of cyclooxygenase that can be easily induced by mitogen, endotoxin, hormone, growth factor, or cytokine. Prostaglandin is a potent mediator for various pathological and physiological processes. The COX-1 plays important physiological roles such as in the release of endogenous prostaglandin, the maintenance of the shape and the function of stomach, and the blood circulation in the kidney. On the other hand, the COX-2 is induced by an inflammatory factor, hormone, a growth factor, or cytokine. Therefore, the COX-2 is involved in pathological processes of prostaglandin, unlike the constitutive COX-1. In this regard, selective inhibitors of the COX-2 produce fewer and less side effects in terms of action mechanism in comparison with conventional nonsteroidal antiinflammatory agents. In addition, they reduce inflammation, pain, and fever and inhibit uterus contraction caused by hormones and growth of several cancers. In particular, they are effective in decreasing side effects such as stomach toxicity and kidney toxicity. Still furthermore, they inhibit the synthesis of contractile prostanoid, thereby leading to suppression of the contraction of smooth muscles. Therefore, they help in preventing premature birth, menstrual irregularity, asthma, and eosinophilic disease.
Recently, it was reported that nonsteroidal antiinflammatory agents are effective in treating large intestine cancer [European Journal of Cancer, Vol 37, p2302, 2001], prostate cancer [Urology, Vol 58, p127, 2001], and dementia [Exp. Opin. Invest. Drugs, Vol 9, p671 , 2000].
In addition, it is anticipated that selective inhibitors of the COX-2 would be effective in treating osteoporosis and glaucoma. Utility of selective inhibitors of the COX-2 is well described in publications [John Vane, "Towards a Better Aspirin" in Nature, Vol.367, pp215-216, 1994; Bruno Battistini, Regina Botting and Y.S. Bakhle, "COX-1 and COX-2: Toward the Development of More Selective NSAIDs" in Drug News and Perspectives, Vol.7, pp501-512, 1994; David B. Reitz and Karen Seibert, "Selective Cyclooxygenase Inhibitors" in Annual Reports in Medicinal Chemistry, James A. Bristol, Editor, Vol. 30, pp179-188, 1995].
Various selective COX-2 inhibitors having different structures are known. Among them, a selective COX-2 inhibitor having a diaryl heterocyclic structure, i.e. a tricyclic structure has been widely studied as a potent candidate. The diaryl heterocyclic structure has a central ring and a sulfonamide or methylsulfone group attached to one of the aryl rings. An initial substance having such diaryl heterocyclic structure is Dup697 [Bioorganic & Medicinal Chemistry Letters, Vol 5, p2123, 1995]. Since then, SC-58635 having a pyrazol ring (Journal of Medicinal Chemistry, Vol 40, p1347, 1997) and MK-966 having a furanone ring (WO 95/00501 ) were discovered as derivatives of the Dup697.
One selective COX-2 inhibitor, Celecoxib of formula 14 is disclosed in U.S. Patent No. 5,466,823. The Celecoxib is a substituted pyrazolyl benzenesulfonamide derivative. Formula 14
Figure imgf000004_0001
Another selective COX-2 inhibitor, Rofecoxib of formula 15 is disclosed in WO 95/00501. The Rofecoxib has a diaryl heterocyclic structure with a central furanone ring.
Formula 15
Figure imgf000004_0002
Valdecoxib of formula 16 as another selective COX-2 inhibitor is disclosed in U.S. Patent No. 5,633,272. The Valdecoxib has a phenylsulfonamide moiety with a central isoxazole ring.
Formula 16
Figure imgf000004_0003
The selective COX-2 inhibitors of formulas 14 to 16 are effective inflammatory therapeutic agents with fewer and less side effects in comparison with conventional nonsteroidal antiinflammatory agents.
Disclosure of the Invention An aspect of the present invention provides a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof.
Another aspect of the present invention provides a method for preparing a pyrazole-3-one derivative or a non-toxic salt thereof. Another aspect of the present invention provides a pharmaceutical composition comprising a pyrazole-3-one derivative or a non-toxic salt thereof as an active ingredient for the treatment of fever, pain, and inflammation.
Yet another aspect of the present invention provides a pharmaceutical composition comprising a pyrazole-3-one derivative or a non-toxic salt thereof as an active ingredient for the treatment of cancers and dementia.
Best mode for carrying out the Invention According to an aspect of the present invention, there is provided a pyrazole-3-one derivative represented by formula 1 : Formula 1
Figure imgf000005_0001
wherein:
Rι and R2 each independently represent Cι-C3 alkyl, aryl, or substituted aryl;
R3 represents amino or methyl;
R4 and R5 each independently represent hydrogen, Cι-C3 alkyl, halogen, methyl substituted with halogen, C C3 alkoxy, cyano, or nitro; or a non-toxic salt thereof. Preferably, the Ri and R2 each independently represent Cι-C3 alkyl; R3 represents methyl; and R4 and Rs each independently represent hydrogen, Cι-C3 alkyl, halogen, or Cι-C3 alkoxy.
Preferably, the position of R4 and R5 is respectively 3- and 4-, 2- and 4-, 3- and 5-, or 3- and 2-, and more preferably 3- and 4-.
The pyrazole-3-one derivative of formula 1 may be present in a form of a non-toxic salt. The term, "non-toxic salt" as used herein refers to a pharmaceutically acceptable, toxin-free salt, including an organic salt and an inorganic salt. The Inorganic salt of the pyrazole-3-one derivative of formula 1 includes an inorganic salt of aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, or zinc but is not limited thereto. Preferably, an inorganic salt of ammonium, calcium, potassium, or sodium is used. The organic salt of the pyrazole-3-one derivative of formula 1 includes an organic amine salt of primary, secondary, or tertiary amine, substituted amine that is present in nature, or cyclic amine, or a salt of a basic ion exchange resin but is not limited thereto. Examples of the salt of a basic ion exchange resin include a salt of arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine,
2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpyperidine,
N-methylglucamine, glucamine, glucosamine, histidine, hydroamine, N-(2-hydroxyethyl)pyperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, pyperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine.
The pyrazole-3-one derivative of formula 1 may be present in a form of an organic acid salt or an inorganic acid salt. Examples of the organic acid salt or the inorganic acid salt of the pyrazole-3-one derivative of formula 1 include a salt of acetic acid, adipic acid, aspartic acid, 1 ,5-naphthalene disulfonic acid, benzene sulfonic acid, benzoic acid, camphor sulfonic acid, citric acid, 1 ,2-ethane disulfonic acid, ethane sulfonic acid, ethylenediaminetetraacetic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, icethionic acid, lactic acid, maleic acid, malic acid, madelic acid, methane sulfonic acid, mucinic acid, 2-naphthalenedisulfonic acid, nitric acid, oxalic acid, pentothenic acid, phosphoric acid, pivalric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, p-toluene sulfonic acid, undecanoic acid, and 10-undecenoic acid. Preferably, a salt of succinic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, phosphoric acid, sulfuric acid, or tartaric acid is used.
The pyrazoIe-3-one derivative of the present invention preferably includes: 5-(4-methanesulfonylphenyl)-4-(4-methoxyphenyl)-1 ,2-dimethyl-1 ,2-dihyd ropyrazole-3-one;
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-phenyl-1 ,2-dihydropyrazole-
3-one;
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-(4-methylphenyl)-1 ,2-dihydr opyrazole-3-one; and
4-(3,4-dichlorophenyl)-5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-1 ,2-dihy dropyrazole-3-one.
According to another aspect of the present invention, there is provided a propionic acid derivative as an intermediate for the synthesis of the pyrazole-3-one derivative of formula 1 , as represented by formula
4:
Formula 4
Figure imgf000007_0001
wherein, R3, R4, and R5 are as defined in formula 1 and RQ represents CrC3 alkyl.
According to another aspect of the present invention, there is provided a method for preparing a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof, comprising reacting a hydrazine derivative of formula 5 with a propionic acid derivative of formula 4. Formula 5
NH— NH R2
wherein, Ri and R2 are as defined in formula 1 . The aforementioned reactions are preferably carried out in a solvent which can be separated from water produced during the reaction by a Dean-Stark trap apparatus. Examples of the solvent include, but are not limited to, benzene, toluene, or xylene. More preferably, toluene is used. The reactions are preferably carried out by heating the reactant to the boiling point of the solvent and completing the reaction. More preferably, toluene is used as a solvent and the reactants are heated to the boiling point of the tolene and refluxed to complete the reaction.
The separation and purification of the reaction products can be performed by concentration or extraction, or other processes, which is conventionally used in organic synthesis process, and optionally by a silica gel column chromatography.
The said propionic acid derivative of formula 4 may be prepared by reacting a sulfonylbenzoic acid derivative of formula 2 with a phenyl acetate derivative of formula 3 in the presence of a base. Formula 2
Figure imgf000008_0001
Formula 3
Figure imgf000008_0002
wherein, R3, R4, and R5 are as defined in formula 1 and RQ represents Cι-C3 alkyl.
The said base includes sodium hydride, potassium carbonate, or potassium hydroxide. Preferably, sodium hydride is used. According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier for the treatment of fever, pain, and inflammation.
The pharmaceutical composition comprises a compound of formula 1 or a non-toxic salt thereof when it is a selective inhibitor of cyclooxygenase-2. Therefore, the pharmaceutical composition can be used as an antipyretic, an analgesic, and an antiinflammatory agent, with reduced side effects.
Conventional nonsteroidal antiinflammatory agents non-selectiveiy inhibit the prostaglandin synthesis enzymes, cyclooxygenase-1 and cyclooxygenase-2. Therefore, various side effects may occur.
. On the other hand, a compound of formula 1 and a non-toxic salt thereof selectively inhibit cyclooxygenase-2. Therefore, the side effects of conventional nonsteroidal antipyretics, analgesics, and antiinflammatory agents can be reduced.
The pharmaceutical composition of the present invention comprises a compound of formula 1 and/or a non-toxic salt thereof and a pharmaceutically acceptable carrier or excipient. Therefore, the pharmaceutical composition may be used as a substitute for conventional nonsteroidal antiinflammatory agents. In particular, due to the reduction of the side effects of conventional nonsteroidal antipyretics, analgesics, and antiinflammatory agents, the pharmaceutical composition of the present invention is useful for treating patients with peptic ulcer, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.
The pharmaceutical composition of the present invention can be used in all inflammatory diseases associated with pathological prostaglandin and is particularly useful in treating osteoarthritis and rheumatoid arthritis which require high dosage of nonsteroidal antiinflammatory agents .
The pharmaceutical composition of the present invention can be administered in form of an adult dosage of 50 mg/kg/day to 400 mg/kg/day of the compound of formula 1. An adequate dosage is determined depending on the degree of disease severity. According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof and a pharmaceutically acceptable carrier for the treatment of cancers and dementia.
Recently, it was reported that nonsteroidal antiinflammatory agents are effective in the treatment of large intestine cancer [European Journal of Cancer, Vol 37, p2302, 2001], prostate cancer [Urology, Vol 58, p127, 2001], and dementia [Exp. Opin. Invest. Drugs, Vol 9, p671 , 2000]. Therefore, it is understood that the pharmaceutical composition of the present invention as a nonsteroidal antiinflammatory agent can also be used for the treatment of these diseases.
The pharmaceutical composition of the present invention can be administered in the form of an adult dosage of 50 mg/kg/day to 400 mg/kg/day of the compound of formula 1 or a non-toxic salt thereof. An adequate dosage is determined depending on the degree of disease severity.
The pharmaceutical composition of the present invention may be administered in the form of tablet, foam tablet, capsule, granule, powder, sustained-release tablet, sustained-release capsule (a single unit formulation or a multiple unit formulation), intravenous and intramuscular injectable solution, infusion solution, suspension, or suppository, or in other suitable dosage forms.
Sustained-release pharmaceutical dosage forms contain active ingredients with or without an initial loading dose. They are wholly or partially sustained-release pharmaceutical dosage forms to release active ingredients in a controlled manner.
Preferably, the pharmaceutical composition is orally administered. The pharmaceutical composition further comprises a pharmaceutically acceptable excipient and/or diluent and/or adjuvant in pharmaceutically effective amounts.
Examples of the excipient and adjuvant include gellatin, a natural sugar such as sucrose and lactose, lecitin, pectin, starch such as corn starch and amylose, cyclodextrin and cyclodextrin derivative, dextran, polyvinylpyrrolidone, poiyvinyl acetate, Arabic gum, arginic acid, xylose, talc, salicylic acid, calcium hydrogen phosphate, cellulose, cellulose derivative such as methylcellulose, methoxypropyl cellulose, hydroxypropylmethyl cellulose, and hydroxypropylmethylcellulose phthalate, fatty acid having 12 to 22 carbon atoms, emulsifying agent, oil and fat, in particular, vegetable glycerol ester and polyglycerol ester of saturated fatty acids, monohydric alcohol, polyhydric alcohol, polyglycol such as polyethylene glycol, aliphatic alcohol having 1 to 20 carbon atoms, or aliphatic saturated or unsaturated fatty acid ester having 2 to 22 carbon atoms with polyhydric alcohols such as glycoi, glycerol, diethylene glycol, 1 ,2-propylene glycol, sorbitol, and mannitol. Other suitable adjuvants include a disintegrating agent.
Examples of the disintegrating agent include a cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, sodium carboxymethyl cellulose, and microcrystalline cellulose. A coating agent which is conventionally used in this field may also be used. Examples of the coating agent include acrylic acid and/or methacrylic acid and/or an ester polymer or copolymer thereof, zein, ethyl cellulose, ethyl cellulose succinate, and Shellac.
A plasticizer suitable for the coating agent is citric ester and tartaric ester, glycerol and glycerol ester, or polyethylene glycol with different chain lengths.
A liquid composition such as solution and suspension is formulated in water or a physiological acceptable organic solvent such as alcohol and aliphatic alcohol.
The liquid pharmaceutical composition may further comprise a preservative such as potassium solvate, methyl 4-hydroxybenzoate, and propyl 4-hydroxybenzoate, an antioxidant such as ascorbic acid, and a fragrant such as peppermint oil.
In addition, when the liquid pharmaceutical composition is formulated, a conventional solubilizer or emulsifier such as polyvinylpyrrolidone and polysolvate 80 may be used.
Other examples of suitable excipients and adjuvants are disclosed in Dr.H.P. Fielder, "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete" [Encyclopaedia of auxiliaries for pharmacy, cosmetics and related fields]. Hereinafter, the present invention will be described more specifically by examples. However, the following examples are provided only for illustration and thus the present invention is not limited to or by them.
Example 1
3-(4-methanesulfonylphenyl)-2-(4-methoxyphenyl)-3-oxo-propionic acid ethyl ester Formula 6
Figure imgf000012_0001
1g of 4-methanesulfony benzoicacid, 970mg of 4-methoxyphenylacetic acid ethyl ester, and 950mg of carbonyldiimidazole were dissoved in 15ml of dimethylformamide and 230mg of sodium hydride were added dropwise to the solution and the mixture was reacted in room temperature for 12 hours. Afterwards, water was added to diute the resultant, followed by extraction with ethyl acetate. The obtained organic layer was dried over anhydrous magnesium sulfate to give 1.5g of the title compound as a light yellow liquid(yield 83%). H-NMR(400MHz, CDCI3) δ 8.14(d, 2H, J=8.8Hz), 8.04(d, 2H, J=8.8Hz), 6.95(d, 2H, J=8.8Hz), 6.65(d, 2H, J=8.8Hz), 5.11(s, 1 H), 4.12(q, 2H), 3.74(s, 3H), 3.10(s, 3H), 1.30(t, 3H)
3-2-phenylpropionic acid methyl ester
Figure imgf000012_0002
1.3g (yield 80%) of the title compound as a liquid was prepared in the same manner as in Example 1 except using 750mg of 4-methoxyphenylacetic acid methyl ester instead of 4-methoxyphenylacetic acid ethyl ester.
1H-NMR(400MHz, CDCI3) δ 8.14(d, 2H, J=8.8Hz), 8.04(d, 2H, J=8.8Hz), 7.14(m, 5H), 5.11 (s, 1H), 3.63(s, 3H), 3.09(s, 3H)
Example 3
3-(4-methanesulfonylphenyl)-3-oxo-2-(4-methylphenyl)propionic acid ethyl ester Formula 8
Figure imgf000013_0001
1.5g (yield 83%) of the title compound as a liquid was prepared in the same manner as in Example 1 except using 0.89mg of 4-methylphenylacetic acid ethyl ester instead of 4-methoxyphenylacetic acid ethyl ester. 1H-NMR(400MHz, CDCI3) δ 8.14(d, 2H, J=8.8Hz), 8.04(d, 2H, J=8.8Hz), 6.94(d, 2H, J=8.8Hz), 6.64(d, 2H, J=8.8Hz), 5.11 (s, 1 H), 4.13(q, 2H), 3.10(s, 3H), 2.35(s, 3H), 1.30(t, 3H)
Example 4
2-(3,4-dichlorophenyl)-3-(4-methanesulfonylphenyl)-3-oxo-propion ic aicd ethyl ester Formula 9
Figure imgf000013_0002
1.7g (yield 85%) of the title compound as a liquid was prepared in the same manner as in Example 1 except using 1.1g of (3,4-dichlorophenyl)acetic acid ethyl ester instead of 4-methoxyphenylacetic acid ethyl ester.
1H-NMR(400MHz, CDCI3) δ 8.14(d, 2H, J=8.8Hz), 8.04(d, 2H, J=8.8Hz), 7.09(d, 1 H, J=8.4Hz), 7.01(s, 1 H), 6.88(d, 1 H, J=8.4Hz), 5.11 (s, 1 H), 4.13(q, 2H), 3.10(s, 3H), 1.30(t, 3H)
Example 5
5-(4-methanesulfonylphenyI)-4-(4-methoxyphenyl)-1 ,2-dimethyl-1 , 2-dihydropyrazole-3-one Formula 10
Figure imgf000014_0001
3-(4-methanesulfonylphenyl)-2-(4-methoxyphenyl)-3-oxo-propionic acid ethyl ester was dissoved in 20ml of toluene and then 0.24g of dimethyl hydrazine was added to the solution. The apparatus containing the mixutre was heated and refluxed at 120°C for 24 hours in the Dean-Stark trap apparatus. The reaction mixture was cooled, diluted with water, and extracted with ethyl acetate. The obtained organic layer was dried on anhydrous magnesium sulfate and concentrated under reduced pressure. The resultant was recrystalized with n-hexane to give 160mg of the title compound as a yellow so!id(yield 53%). 1H-NMR(400MHz, CDCI3) δ 8.02(d, 2H, J=8.0Hz), 7.59(d, 2H, J=8.0Hz), 7.26(d, 2H, J=8.0Hz), 6.83(d, 2H, J=8.0Hz), 3.81 (s, 3H), 3.51 (s, 3H), 3.15(s, 3H), 3.06(s, 3H) FAB Mass(M+1):373 IR: (υ C=0) 1637cm"1 Melting point: 245-247 °C
Example 6
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-phenyl-1 ,2-dihydropyr azole-3-one
Formula 11
Figure imgf000015_0001
170 mg (yield 56%) of the title compound was prepared in the same manner as in Example 5 except using 0.3g of 3-(4-methanesulfonylphenyl)-3-oxo-2-pheny!propionic acid methyl ester instead of
3-(4-methanesulfonylphenyl)-2-(4-methoxyphenyl)-3-oxo-propionic acid ethyl ester.
1H-NMR(400MHz, CDCI3) δ 7.98(d, 2H, J=8.0Hz), 7.54(d, 2H, J=8.0Hz), 7.28-7.19(m, 5H), 3.47(s, 3H), 3.11 (s, 3H), 3.06(s, 3H) El Mass(M+) : 342 IR: (υ C=0) 1640cm"1 Melting point: 210-212°C
Example 7
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-(4-methylphenyl)-1 ,2- dihydropyrazole-3-one Formula 12
Figure imgf000015_0002
180 mg (yield 60%) of the title compound was prepared in the same manner as in Example 5 except using 0.3g of 3-(4-methanesulfonylphenyl)-3-oxo-2-(4-methylphenyl)propionic acid ethyl ester instead of 3-(4-methanesulfonylphenyl)-2-(4-methoxyphenyl)-3-oxo-propionic acid ethyl ester
1H-NMR(400MHz, CDCI3) δ 7.99(d, 2H, J=8.0Hz), 7.55(d, 2H, J=8.00Hz), 7.17(d, 2H, J=8.00Hz), 7.02(d, 2H, J=8.00Hz), 3.50(s, 3H), 3.08(s, 3H) 3.05(s, 3H), 2.29(s, 3H) El Mass(M+):356 IR: (υ C=O) 1626cm"1 Melting point: 247-249 °C
Example 8
4-(3,4-dichlorophenyl)-5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-1 ,2-dihydropyrazole-3-one Formula 13
Figure imgf000016_0001
190 mg (yield 57%) of the title compound was prepared in the same manner as in Example 5 except using 0.3g of 2-(3,4-dichlorolphenyl)-3-(4-methanesulfonylphenyl)-3-oxo-propionic acid ethyl ester instead of 3-(4-methanesulfonylphenyl)-2-(4-methoxyphenyl)-3-oxo-propionic acid ethyl ester.
1H-NMR(400MHz, CDCI3) δ 7.98(d, 2H, J=8.0Hz), 7.49(d,2H,J=8.0Hz), 7.44(d, 1 H,J=8.0Hz), 7.35(s,1 H), 7.07(d, 1 H, J=8.0Hz), 3.14(s, 3H), 3.09(s, 3H), 3.08(s, 3H) El Mass(M+):411
IR: (υ C=O) 1637cm"1 Melting point: 240-242 °C
Experiments 1. Evaluation of selective COX-2 inhibitory activity
1) Method In order to pharmacologically determine the selective COX-2 inhibitory activity, the percentages of the COX-1 and COX-2 inhibition of the compounds of the present invention illustrated in the Examples were measured by the following methods.
a. Assay for the COX-1 inhibitory activity using U-937
U-937 human lymphoma cells (Korean Cell Line Bank, Seoul, Korea, Accession Number: 21593) were cultured and centrifuged. The collected cells were diluted with HBSS (x1 , Hank's balanced salt solution) to a concentration of 1 x 106 cells/ml. 1 ml of the dilute cell solution was placed into each well of 12-well plates. 5 μJL of 1 μ M solution of a test compound in DMSO and 5 μi of DMSO as a control were added to the wells. The wells were incubated in C02 incubator at 37 "C for 15 minutes. Separately, 10 mM stock solution of arachidonic acid in ethanol was diluted ten times in ethanol to prepare 1 mM solution of arachidonic acid. Arachidonic acid acts as a substrate. 10 μi of the 1 mM solution of arachidonic acid was added to each well and incubated at CO2 incubator at 37 °C for 30 minutes. The cell solution of each well was placed in a centrifuge test tube and centrifuged at 10,000 rpm at 4°C for 5 minutes. The concentration of PGE2 in the collected cells and the supernatant was quantified by means of a monoclonal kit (Cayman Chemicals). The percentages of PGE2 inhibition in a group of the test compound-treated cells in relation to a group of the DMSO-treated cells were calculated. Based on the calculated values, the COX-1 inhibitory activities were evaluated.
b. Assay for the CQX-2 inhibitory activity using RAW 264.7 cell line
2 x 106 cells of RAW 264.7 cell line (Korean Cell Line Bank, Seoul, Korea, Accession Number: 40071 ) were inoculated into each well of 12-well plates. Each well was treated with 250 μ M of aspirin and incubated at 37 °C for 2 hours. After the culture media were replaced with new culture media, the new culture media were treated with a test compound (10 nM) and incubated for 30 minutes. Then, each well was treated with interferon γ (100 units/ml) and lipopolysaccharide (LPS, 100 ng/ml) and incubated for 18 hours. The culture media were transferred to other test tubes. The concentration of PGE2 was quantified by means of the EIA kit (Cayman Chemicals).
2) Test results The test results are presented in Table 1 below. The percentages of the COX inhibition were calculated according to the following equation:
% Inhibition = (concentration of PGE2 in test compound-untreated sample - concentration of PGE2 in test compound-treated sample) / (concentration of PGE2 in test compound-untreated sample) x 100
Cyclooxygenase (COX) Inhibition (%)
Samples COX-1 (1 μ M) COX-2 (10 nM)
Reference (Valdecoxib) 28.8 5.47 Example 5 10.5 22.5 Example 6 22.6 13.2 Example 7 36.5 12.5
3) Evaluation
The in vitro test results about the percentages of the COX-1 and COX-2 inhibition are listed in Table 1.
As shown in Table 1 , inhibition (%) ratios of COX-2 to COX-1 in Examples 5 to 7 were significantly higher than that in the reference, Valdecoxib. This indicates that selective inhibition of COX-2 to COX-1 of the present compound is superior to that of the reference.
The compounds of Examples 5 to 7 exhibited the COX-2 inhibitory activities significantly higher than the reference. Based on this result, it can be seen that the present compounds have reduced side effects due to enhanced selectivity and improved relief effects of fever, pain, and inflammation, compared to the reference.
Industrial Applicability
As apparent from the above description, the present invention provides a pyrazole-3-one derivative or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient. The pharmaceutical composition is effective in reducing fever, pain, and inflammation. In particular, as a result of reduction of the side effects of conventional nonsteroidal antiinflammatory agents, the pharmaceutical composition is useful for treating patients with peptic ulcer disease, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the following claims.

Claims

What is claimed is:
1. A pyrazole-3-one derivative represented by formula 1 : Formula 1
Figure imgf000020_0001
wherein:
Ri and R2 each independently represent Cι-C3 alkyl, aryl, or substituted aryl;
R3 represents amino or methyl; R and R5 each independently represent hydrogen, CrC3 alkyl, halogen, methyl substituted with halogen, C1-C3 alkoxy, cyano, or nitro; or a non-toxic salt thereof.
2. The pyrazole-3-one derivative according to claim 1 wherein Ri and R2 each independently represent C-i-C3 alkyl; R3 represents methyl; and R and R5 each independently represent hydrogen, C-ι-C3 alkyl, halogen, or C1-C3 alkoxy; or a non-toxic salt thereof.
3. The pyrazole-3-one derivative according to claim 1 , which is selected from the group consisting of:
5-(4-methanesulfonylphenyl)-4-(4-methoxyphenyl)-1 ,2-dimethyl-1 ,2-dihyd ropyrazole-3-one;
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-phenyl-1 ,2-dihydropyrazole- 3-one;
5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-4-(4-methylphenyl)-1 ,2-dihydr opyrazole-3-one; and 4-(3,4-dichlorophenyl)-5-(4-methanesulfonylphenyl)-1 ,2-dimethyl-1 ,2-dihydropyrazole-3-one. or a non-toxic salt thereof.
4. A propionic acid derivative represented by formula 4: Formula 4
wherein, R3, R4, and R5 are as defined in claim 1 and Re represents C1-C3 alkyl.
5. A method for preparing a pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof, comprising reacting a hydrazine derivative of formula 5 with a propionic acid derivative of formula 4:
Formula 1
Figure imgf000021_0002
Formula 5
Figure imgf000021_0003
Formula 4
Figure imgf000022_0001
wherein:
Ri , R2, R3, R4 and R5 are as defined in claim 1 and Re represents C1-C3 alkyl.
6. A method according to claim 5, wherein the propionic acid derivative of formula 4 is prepared by reacting a sulfonylbenzoic acid derivative of formula 2 with a phenyl acetate derivative of formula 3 in the presence of a base.
Formula 2
Figure imgf000022_0002
Formula 3
Figure imgf000022_0003
R3, R4 and R5 are as defined in claim 1 and Re represents C1-C3 alkyl.
7. A pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative or a non-toxic salt thereof according to claim 1 to claim 3 as an active ingredient and a pharmaceutically acceptable carrier for the treatment of fever, pain, and inflammation.
8. A pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative or a non-toxic salt thereof according to claim 1 to claim 3 as an active ingredient and a pharmaceutically acceptable carrier for the treatment of cancers.
9. A pharmaceutical composition comprising a therapeutically effective amount of a pyrazole-3-one derivative or a non-toxic salt thereof according to claim 1 to claim 3 as an active ingredient and a pharmaceutically acceptable carrier for the treatment of dementia.
PCT/KR2003/001172 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same WO2004000206A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004515206A JP4257292B2 (en) 2002-06-24 2003-06-16 Pyrazol-3-one derivatives, methods for their preparation, and pharmaceutical compositions containing them
EP03760957A EP1515952A4 (en) 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2003232684A AU2003232684A1 (en) 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0035411 2002-06-24
KR10-2002-0035411A KR100478467B1 (en) 2002-06-24 2002-06-24 Pyrazol-3-one derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
WO2004000206A2 true WO2004000206A2 (en) 2003-12-31
WO2004000206A3 WO2004000206A3 (en) 2004-03-25

Family

ID=29774937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/001172 WO2004000206A2 (en) 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same

Country Status (7)

Country Link
US (1) US6689805B2 (en)
EP (1) EP1515952A4 (en)
JP (1) JP4257292B2 (en)
KR (1) KR100478467B1 (en)
CN (1) CN1662507A (en)
AU (1) AU2003232684A1 (en)
WO (1) WO2004000206A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103601681A (en) * 2013-11-29 2014-02-26 郑州大学 3,5-pyrazoldione derivative containing exocyclic double bond structure unit and preparation method and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990080440A (en) * 1998-04-17 1999-11-05 성재갑 Novel Pyrazole Derivatives
JP2000239555A (en) * 1999-02-16 2000-09-05 Chemiprokasei Kaisha Ltd Use of arylidenebis-pyrazolone derivative
WO2001016138A1 (en) * 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
KR20020030124A (en) * 1999-09-22 2002-04-22 프리돌린 클라우스너, 롤란드 비. 보레르 Pyrazole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57176963A (en) * 1981-04-25 1982-10-30 Otsuka Chem Co Ltd Preparation of 1,3-di-substituted-5-pyrazolone derivative
JPS62108814A (en) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd Inhibitor against formation of peroxide lipide
JPS6456664A (en) * 1987-08-27 1989-03-03 Nissan Chemical Ind Ltd Pyrazole derivative and insect pest controlling agent
EP0603964B1 (en) * 1992-12-23 1999-03-10 Eastman Kodak Company Azopyrazolone masking couplers
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DE60004001T2 (en) * 1999-12-03 2004-04-15 Pfizer Products Inc., Groton Acetylene derivatives for use as an analgesic or anti-inflammatory

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990080440A (en) * 1998-04-17 1999-11-05 성재갑 Novel Pyrazole Derivatives
JP2000239555A (en) * 1999-02-16 2000-09-05 Chemiprokasei Kaisha Ltd Use of arylidenebis-pyrazolone derivative
WO2001016138A1 (en) * 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
KR20020030124A (en) * 1999-09-22 2002-04-22 프리돌린 클라우스너, 롤란드 비. 보레르 Pyrazole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1515952A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103601681A (en) * 2013-11-29 2014-02-26 郑州大学 3,5-pyrazoldione derivative containing exocyclic double bond structure unit and preparation method and application thereof
CN103601681B (en) * 2013-11-29 2015-12-09 郑州大学 Containing 3, the 5-pyrazodione derivatives and its production and use of exocyclic double bond structural unit

Also Published As

Publication number Publication date
CN1662507A (en) 2005-08-31
US20040002532A1 (en) 2004-01-01
KR100478467B1 (en) 2005-03-23
US6689805B2 (en) 2004-02-10
KR20040000221A (en) 2004-01-03
EP1515952A2 (en) 2005-03-23
JP2006504639A (en) 2006-02-09
EP1515952A4 (en) 2007-06-06
AU2003232684A1 (en) 2004-01-06
JP4257292B2 (en) 2009-04-22
WO2004000206A3 (en) 2004-03-25
AU2003232684A8 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
US7019144B2 (en) 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
US6689805B2 (en) Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
US6727268B2 (en) 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
US6849652B1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
US7473700B2 (en) 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
US6777434B2 (en) Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same
US7230010B2 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
US7781592B2 (en) Thione derivative, method for the preparation thereof, and pharmaceutical composition containing the same
JP2006504756A (en) Isothiazole derivative, process for producing the same and pharmaceutical composition
KR100484526B1 (en) Thione derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
KR100641280B1 (en) 1,2-Dithiole-3-thione derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
KR100576343B1 (en) 1,2,4-Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
KR20050052617A (en) Pyridazine-4-one derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003760957

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004515206

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038145782

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003760957

Country of ref document: EP